Substance Withdrawal Syndrome Clinical Trial
Official title:
Evaluation of the Standardised Nurse-led Approach for Risk Screening and Decrease of Alcohol Withdrawal Among Adult Inpatients With Alcohol Dependence in an Ear, Nose, Throat and Jaw Surgery Department
In ear, nose, throat (ENT) and jaw surgery departments, up to 60% of patients suffer from
alcohol dependence (Allen et al., 2009), and may develop an alcohol withdrawal syndrome
(AWS) when undergoing sur-gery. Caring for these patients creates a major challenge for all
persons involved: Health care staff is not only challenged by the primary illness but also
by increased risk of life-threatening complications (infection, bleeding, cardiopulmonary
dysfunction, impaired wound healing, re-operation), higher mortality rate, and longer
duration of hospitalization due to preoperative alcohol use and the development of an AWS
(Delgado-Rodriguez, Gomez-Ortega, Mariscal-Ortiz, Palma-Perez, & Sillero-Arenas, 2003; Eyer
et al., 2011; Foy, Kay, & Taylor, 1997; Genther & Gourin, 2012; Kuo et al., 2008; Mayo-Smith
et al., 2004; McCusker, Cole, Abrahamowicz, Primeau, & Belzile, 2002; Neyman, Gourin, &
Terris, 2005; O'Brien et al., 2007). Moreover, nearly five percent of all patients with an
AWS develop an alcohol withdrawal delirium (AWD) which, without any therapy, will end
lethally in 15% of all cases. With adequate medical and other interventions lethality is
about two percent (Diener, 2003; Wright, Myrick, Henderson, Peters, & Malcolm, 2006).
Additionally, the occurrence of an AWS and / or AWD represents a threatening, time-intensive
and complex situation for family members (Repper-DeLisi et al., 2008; Yu et al., 2012).
Since 2011, in addition to patients undergoing short-term surgery, also patients with
oncological diagnoses are hospitalized in the ENT and Jaw Surgery Department at the
University Hospital Basel (USB). These patients are in need of prolonged surgical treatments
and resulting longer periods of abstinence from food and drink, including alcohol and other
substances, increase the risk of alcohol withdrawal. For instance, in the ENT and Jaw
Surgery Department, in 2011, 74 out of 910 inpatients were at risk for or already
experienced an AWD and 47 of them needed permanent supervision to guarantee their safety.
Bridging the period of abstinence by drinking alcohol pre- and postoperatively is a
suboptimal option for these patients due to the relatively long surgical treatment. This
situation called for action: based on positive experiences within the
dementia-delirium-programme of USB (Hasemann & Pretto, 2006), an evidence-based approach to
screen for, detect and treat AWS and / or AWD in ENT and jaw surgery patients was developed
and implemented (Hasemann, 2013). Now, this new approach needs to be evaluated.
The aims of the proposed study are to describe patient trajectories and to evaluate the
processes and structures of the nurse-led approach in the ENT and Jaw Surgery Department at
USB. The following research questions were generated:
Aim 1): Who are the patients captured with the algorithm, what are their risk factors, and
how are the patient trajectories in terms of decisions, development, start, duration and
ending of AWS and / or AWD? Specific questions asked:
- Which are demographic and medical characteristics of patients?
- How many patients are at risk for AWD / AWS?
- Which decisions do patients make?
- What is the time of onset, duration and ending of AWS and / or AWD?
- Were additional resources used to guarantee safety of patients?
Aim 2): How is the prevention algorithm adhered to? Specific questions asked:
- How many patients were risk-assessed by a nurse at hospital admission?
- How many patients or those who should have been asked were eventually asked to agree to
substitution therapy?
- How many patients at risk were assessed using the Clinical Institute Withdrawal
Assessment (CIWA)-Ar?
- How many times was the delirium expert consultation service contacted due to reasons
stated in algorithm?
;
Time Perspective: Retrospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00114439 -
Lithium Cannabis Withdrawal Study
|
Phase 2 | |
Completed |
NCT00980044 -
Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal
|
Phase 2/Phase 3 | |
Completed |
NCT02643355 -
Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED
|
N/A | |
Recruiting |
NCT00792415 -
Validation of a Pediatric-Specific Abstinence Syndrome Assessment Tool
|
N/A | |
Completed |
NCT02431728 -
The Effect of Melatonin Upon Post-Acute Withdrawal Among Males in a Residential Treatment Program
|
Phase 1/Phase 2 | |
Completed |
NCT00695864 -
Effect of Ondansetron for Withdrawal Symptoms
|
N/A | |
Active, not recruiting |
NCT02951793 -
Abuse and Addiction in ICU
|
||
Completed |
NCT02108626 -
Electronic Cigarettes in Daily Dependent Smokers
|
Phase 4 | |
Recruiting |
NCT04917185 -
EA for PAAS: A pRCT
|
N/A | |
Completed |
NCT02801357 -
Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction
|
Phase 1 | |
Completed |
NCT01362959 -
Nicotine Replacement Therapy in the Intensive Care Unit
|
Phase 4 | |
Completed |
NCT00992979 -
Therapeutic Massage to Manage Withdrawal Related Anxiety
|
Phase 2 | |
Completed |
NCT02825459 -
Does Abstinence From E-cigarettes Produce Withdrawal Symptoms?
|
N/A | |
Completed |
NCT00900900 -
The Effects of One-Time Pregnenolone, Dehydroepiandrosterone (DHEA), or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers
|
Phase 2 | |
Completed |
NCT02318290 -
Opioids Withdrawal Syndrome in Critically Ill Patients: a Multicenter Prospective Cohort Study
|
N/A | |
Completed |
NCT00032968 -
Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1
|
Phase 3 | |
Completed |
NCT03374722 -
Opioid Withdrawal Symptoms in Critically Ill Patients
|
||
Completed |
NCT03435614 -
Signs and Symptoms of Opioid-associated Iatrogenic Withdrawal in Critically Ill Adults
|
||
Completed |
NCT00570219 -
The Effect of Valproate on Benzodiazepine Withdrawal Severity
|
N/A | |
Completed |
NCT00367874 -
Treatment of Polydrug-Using Opiate Dependents During Withdrawal
|
Phase 4 |